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Abstract
The management of patients with partial thickness (second
degree) burns is problematic due to the different treatments
needed for varying depths of injury. A report recently published in
The Lancet describes a novel treatment for deep second degree
burns using a fetal skin construct (FSC). The authors included
eight pediatric patients with small second degree burns. They
showed that FSCs reduced the need for autografting of deep
second degree burns, with little hypertrophy of new skin and no
skin contraction. This technology is new and exciting, but in our
opinion several issues must be addressed before FSCs can enter
the clinical arena. All of the patients were included in the treatment
group, and therefore no comparison with conventional skin
substitutes was possible. There is no mention of the use of laser
Doppler in any initial assessment of patients. The debridement
carried out before application of the FSC is not elaborated upon,
and the surface areas involved in the study were very small in most
cases, which limits the relevance to patients with larger burns. The
use of FSCs gives us an additional option in a range of possible
treatments for this notoriously difficult-to-treat patient group.
Introduction
Partial thickness (second degree) burns involve all of the
epidermis and some of the underlying dermis. Management
and subsequent recovery depend on the amount of viable
dermis remaining. A superficial partial thickness burn down to
the papillary dermis will produce blistering, a painful pink
wound bed with good capillary refill, and should heal with
minimal amounts of hypertrophic scar formation in about
14–21 days. A deep partial thickness burn down to the
reticular dermis will also produce blistering, but the wound
bed may be paler and less painful, and there will be reduced
or absent capillary refill. The wound will take longer than
21 days to heal, and the resulting scarring is likely to be poor,
with significant wound contraction [1]. In the clinical setting
the patient is unlikely to present with a wound that matches
either of these descriptions, and so a thorough examination,
together with use of laser Doppler, will help in the initial
assessment of each wound. Considerable experience is
needed to arrive at a clinical management decision.
Treatment of partial thickness burns
Established techniques
As outlined above, the initial management involves clean
debridement of the blistered areas and thorough examination
of the wound bed, along with laser Doppler imagery. Closing
the wound quickly will help to reduce painful stimuli to the
patient. Superficial partial thickness burns usually only require
nonadherent dressings such as Mepitel™ (Mölnlycke Health
Care, Newtown, PA, USA); mid-partial thickness burns
require the use of dressings or occasionally skin substitutes
such as Biobrane™ (Bertek Pharmaceuticals Inc, Morgan-
town, West Virginia, USA) or TransCyte™ (Advanced Tissue
Sciences, La Jolla, CA, USA).
Mepitel™ is a porous, semitransparent, low-adherence wound
contact layer that consists of a flexible polyamide net coated
with soft silicone. The silicone coating is slightly tacky, which
facilitates the application and retention of the dressing to the
peri-wound area. The dressing is placed directly onto the
wound and secured with a bandage. Follow up is then
normally carried out in the clinic every 48–72 hours until the
wound is healed, typically 14–21 days.
Biobrane™ is a biocomposite dressing made from an
ultrathin, semipermeable silicone membrane mechanically
bonded to a flexible knitted trifilament nylon fabric. Purified
peptides derived from porcine dermal collagen are bonded to
the dressing to give an adherent, hydrophilic dressing. It is
applied under aseptic conditions immediately following
debridement of the burn wound. The wound may be
inspected through the dressing when the outer bandage is
replaced. Biobrane™ is usually removed after 7–14 days once
the underlying tissue is healed.
Commentary
Tissue engineered fetal skin constructs for pediatric burns
William B Norbury1, Marc G Jeschke2 and David N Herndon3
1Burns Research Fellow, Department of Surgery, Shriners Hospitals for Children, Galveston, Texas, USA
2Assistant Professor, Department of Surgery, Shriners Hospitals for Children, Galveston, Texas, USA
3Chief of Staff, Professor of Surgery, Jesse H Jones Distinguished Chair in Burn Surgery, Department of Surgery, Shriners Hospitals for Children,
Galveston, Texas, USA
Corresponding author: David N Herndon, dherndon@utmb.edu
Published online: 17 October 2005 Critical Care 2005, 9:533-534 (DOI 10.1186/cc3881)
This article is online at http://ccforum.com/content/9/6/533
© 2005 BioMed Central Ltd534
Critical Care    December 2005 Vol 9 No 6 Norbury et al.
TransCyte™ is another type of skin substitute that is used in
the treatment of mid-dermal to indeterminate depth burn
wounds that typically require debridement and that may be
expected to heal without autografting. It consists of a polymer
membrane and newborn human fibroblast cells cultured
under aseptic conditions in vitro on a nylon mesh. Like the
dressings described above, it is applied under aseptic
conditions to a freshly debrided wound bed. It can also be
removed at a similar time after tissue healing. Kumar and
coworkers [2] showed us that, when used in children,
TransCyte™ promotes faster re-epithelialization than does
Biobrane™, with less need for autografting. However, a
drawback is the increased cost of the dressing.
Deep partial thickness burns usually require skin substitutes
but they may need excision and autografting. An important
initial aim in the treatment of partial thickness burns is to
prevent bacterial infection, which can lead to conversion to a
full thickness burn. The incidence of conversion increases
with depth of burn
Recent advances
In a recent study conducted by Hohlfeld and coworkers [3],
fetal skin constructs (FSCs) were produced using a single
donation of fetal skin (4 cm2 biopsy taken from a terminated
pregnancy at 14 weeks of gestation, following written
informed consent from the donor patient). The cells were
expanded and grown in Dubecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum and frozen in liquid
nitrogen before matrix seeding on native horse collagen
sheets. The FSCs were then placed on lesions after
debridement and at each dressing change (every 3–4 days)
for a maximum of 3 weeks. (For a more detailed description,
see the original report [3].) The authors included eight
pediatric patients with small second degree burns. They
showed that FSCs reduced the need for autografting of deep
second degree burns, with little hypertrophy of new skin and
no skin contraction.
Despite the enthusiasm for this new technology, in our
opinion there are several questions and issues that must be
addressed. The authors mention that the FSCs were placed
on lesions after debridement, but what level of debridement
was this? To what level did they excise? What technique did
they use – sharp debridement with a Watson knife or
dermatome, or simply application of moist gauze, as in the
normal initial debridement of such wounds? The study only
included eight patients, all of whom received the FSC. Before
we may consider introducing this new treatment into routine
practice, it should be tested against the other leading
dressings used in this level of injury. A randomized controlled
trial should be performed comparing the different treatment
options for similar deep partial thickness burns. Once this has
been done we will be able to determine whether there is an
overall benefit for the patient.
Apart from the use of FSCs, several other new technologies
are emerging for the management of second degree burn
wounds. Thus, we suggest that the ideal treatment has yet to
be established and that several factors must be included in
the equation, such as applicability, cost, efficacy and
availability. Recent advances include use of glycerolized
cadaver allograft skin for the treatment of deep partial
thickness facial burns; Horch and coworkers [4] recently
used this approach and found a significant reduction in
hypertrophic scarring as compared with use of topical
agents. Also, Rab and coworkers [5] promoted the ‘Viennese
concept’ of the use of allogeneic cultivated keratinocytes in
the treatment of tangentially excised deep partial thickness
burns, the results of which are most promising. Finally,
Branski and coworkers, from our unit, showed that amnion is
of great benefit in the treatment of partial thickness burns to
the face, resulting in significantly reduced rates of infection
and hypertrophic scarring (L Branski and coworkers,
unpublished data).
Conclusion
The use of FSCs gives us an additional option in a range of
possible treatments for this notoriously difficult-to-treat
patient group. In our opinion, Hohlfeld and coworkers [3]
have reported a very interesting study that suggests
significant benefit for patients. However, the value of the
results is limited by the small number of patients included, the
lack of comparisons or controls, and the small burn size. We
feel that this treatment requires further investigation but that it
must be proven to provide cost-effective benefit to patients
before it may be considered for routine application in the
clinical setting.
Competing interests
The author(s) declare that they have no competing interests.
References
1. Monafo W: Wound care. In Total Burn Care, 2nd ed. 2002:109-
119.
2. Kumar RJ, Kimble RM, Boots R, Pegg SP: Treatment of partial-
thickness burns: a prospective, randomized trial using Tran-
scyte. A NZ J Surg 2004, 74:622-626.
3. Hohlfeld J, de Buys Roessingh A, Hirt-Burri N, Chaubert P,
Gerber S, Scaletta C, Hohlfeld P, Applegate LA: Tissue engi-
neered fetal skin constructs for paediatric burns. Lancet 2005,
366:840-842.
4. Horch RE, Jeschke MG, Spilker G, Herndon DN, Kopp J: Treat-
ment of second degree facial burns with allografts: prelimi-
nary results. Burns 2005, 31:597-602.
5. Rab M, Koller R, Ruzicka M, Burda G, Kamolz LP, Bierochs B,
Meissl G, Frey M: Should dermal scald burns in children be
covered with autologous skin grafts or with allogeneic culti-
vated keratinocytes? – ‘The Viennese concept’. Burns 2005,
31:578-586.